In the Poster Session dedicated to genitourinary cancers held on Sunday, June 2, 2024, at this year’s American Society of Clinical Oncology Annual Meeting in Chicago, Dr. Alicia Morgans presented a post hoc analysis of the ARAMIS trial of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), which aimed to assess the association between prostate-specific antigen (PSA) kinetics and radiological progression in this population. ...
nmCRPC
Advertisement
Latest News
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
A clinical trial sought to determine if flutamide is more effective with or without PROSTVAC in patients with nmCRPC.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA.
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Advertisement
